In this study, we evaluated the relationship between follow-up MRI findings of specific tissues and laboratory results in pyogenic spondylodiscitis. Follow-up MRI findings may demonstrate variable responses according to the tissue. The CRP level was best correlated with changes in the soft tissue, while ESR had the highest association with bony changes.
The treatment of spondylodiscitis is focused on eradicating the infection, and restoring or preserving the spinal structure and stability (2, 7). Monitoring spondylodiscitis can be complex, because the diagnosis is based on clinical, laboratory, and radiologic information. A clinical practice guideline of the Infectious Disease Society of America recommends monitoring systemic inflammatory markers after 4 weeks of antimicrobial therapy (12). Unchanged or increasing values should increase the suspicion for treatment failure. However, follow-up imaging is not routinely recommended for a patient with favorable clinical and laboratory response, but is selectively recommended in those with poor clinical response (12-14). The criteria for discontinuing antimicrobial treatment includes symptom resolution or improvement and normalization of ESR or CRP (8).
Although clinical symptoms are an important factor, they can be subjective and non-specific. Therefore, laboratory results may be more reliable and objective criteria. ESR and CRP are useful inflammatory markers for diagnosing and monitoring infections (12, 15, 16). The ESR is affected by increasing concentrations of fibrinogen, the main clotting protein, during an inflammatory reaction. In contrast, CRP is primarily produced by the liver in response to cytokines such as interleukin-1 (17, 18). CRP has a rapid response to inflammation due to its short half-life, compared to a slow response of ESR (18). In the early phase of an infection or inflammation, CRP can rise before ESR does. In contrast, in the resolving phase, CRP normalizes while ESR remains elevated. Therefore, CRP is a more sensitive and specific acute phase reactant, and is also more responsive to changes in the patient’s condition than is ESR. In patients with acute spondylodiscitis, elevated CRP values returned to normal within 3 months of successful treatment (7, 18). However, in the case of detecting low-grade bony or joint infections, or autoimmune diseases such as systemic lupus erythematous, ESR may be a better marker (18). In spondylodiscitis, ESR is elevated in over 90% of cases regardless of severity of infection or the patient’s age. A reduction in ESR below 25% of its presenting value is known to be a good prognostic marker (7).
Several previous studies have examined the findings and roles of follow-up MRI in spondylodiscitis (9-11, 19-22). Although MRI is currently the imaging modality of choice for evaluating spondylodiscitis, its role in follow-up surveillance has not been established (12). Numaguchi et al. described that persistent enhancement can be seen in both the bone and disc despite clinical improvement (20). Gillams et al. reported progression in bone or disc changes despite clinical improvement (9). Kowalski et al. reported that soft tissue findings, rather than bone findings, on follow-up MRI are related to clinical status based on symptoms and sign (11). Kowalski et al. suggested that a patient’s clinical status and inflammatory biomarker response would be helpful for selecting patients at high risk of treatment failure who may require follow-up MRI (10). However, neither of these markers is ideal. Clinical symptoms can be subjective, while laboratory results are not specific to the location of the infection. Furthermore, there may be a discrepancy between tests. In terms of cost analysis on routine follow-up MRI in patients with pyogenic spondylodiscitis, clinical findings and laboratory markers may be satisfactory to monitor the therapeutic response. However, laboratory markers are systemic, so local problem needs to be checked with MRI complementarily along with clinical symptoms. To the best of our knowledge, this is the first study that compares imaging findings with laboratory results in spondylodiscitis. Knowledge of this relationship might be helpful not only in deciding the necessity of follow-up MRI, but also in interpreting follow-up MRIs.
In our study, CRP was best correlated with soft tissue changes, while ESR was best correlated with bone changes. The mechanism for this relationship is not clear. It might be related with the rapid improvement in CRP and soft tissue findings, compared to those in ESR and bone. The persistent bone signal change in MRI despite the clinical improvement might be related with the abundant vascular supply or increasing granulation tissue in bone (11). The slow healing of bone compared to in soft tissue, and the relatively longer half-life of ESR (compared to that of CRP) may have influenced our results. The disc height never improved in our study, and was thought to be a sequelae of spondylodiscitis regardless of disease progression or improvement. In some studies, authors evaluated the disc signal change or enhancement (9, 11, 20). However, we did not assess disc signal change due to the wide observer variability in our preliminary evaluation.
It is not clearly established how to follow MRI after the treatment of spondylodiscitis, but routine follow-up of MRI is not recommended (12). In case of follow-up MRI due to clinical issue such as back pain or radiculopathy without laboratory abnormality, signal change especially in bone can be interpreted carefully because it may be a slow response to a favorable therapy. If soft tissue findings are improving or improved, they are favorable responses. In case of laboratory abnormality, however, MRI can be required to differentiate the condition as unfavorable treatment response or problem other than spine. Soft tissue findings seem to be more reliable than bone findings to judge the response to therapy (11).
There are several limitations in this study. First, we only observed the relationship between laboratory findings and imaging findings without considering clinical decision for therapeutic response which might change the treatment plan. In our study population, additionally, there were no cases which antibiotic regimen changed or surgical treatment performed as regarded progressive disease although both ESR and CRP at the time of follow-up MRI were resolving or resolved. Second, the sample size of patients was small. Therefore, a larger population study is required to validate our results. The third is the narrow inclusion criteria. We only included patients with medical therapy who underwent follow-up MRI due to analysis difficulties on post-operative images, which were caused by artifacts. This method may have restricted our results to relatively mild forms of spondylodiscitis. The fourth limitation is that there was a time interval between the imaging and laboratory results. Although we examined laboratory results from the closest date with MRI, we observed relatively rapid changes in the laboratory results (and especially in CRP). These changes may have changed the subgroups (e.g. resolving to resolved group) by even a few day intervals. Furthermore, we did not account for differences caused by the etiologic pathogens. Different pathogens and antibiotics may alter the clinical course; however, due to the small number of subjects, we could not consider the differences caused by the pathogens and antibiotics. Finally, we analyzed the MRI using a consensus manner without assessing inter-observer agreement.